Introduction

Diabetes mellitus (DM) is caused by genetic and environmental interactions, along with changing lifestyles and an aging population, increasing incidence of diabetes. Diabetic neuropathy is one of the major complications of diabetes with both Type 1 and Type 2. Up to 50% of all diabetes have polyneuropathy which is a major cause of morbidity and associated with increased mortality, and up to 26% of diabetics develop painful diabetic neuropathy with debilitating effects on quality of life [1–3].

The rising incidence of diabetes and its negative impact on quality of life highlights the urgent need to develop biomarkers of early nerve damage. Measurement of total vitamin B12 has some limitations. We want to determine the levels of urinary methylmalonic acid and its relationships with serum vitamin B12 and polyneuropathy. The 176 Chinese patients with Type 2 diabetes mellitus were divided into 3 groups according to the levels of vitamin B12. A gas chromatography mass spectrometric technique was used to determine blood methylmalonic acid and urinary methylmalonic acid. The diagnosis of distal diabetic polyneuropathy was based on the determination of bilateral limb sensory and motor nerve conduction velocity and amplitude with electromyogram. Multiple regression analysis revealed that urinary methylmalonic acid/creatinine, blood methylmalonic acid, and so forth were variables that influenced diabetic polyneuropathy significantly. Nerve sensory conduction velocity and nerve amplitude in the group of urinary methylmalonic acid/creatinine $>3.5\text{ mmol/mol}$ decreased significantly. Superficial peroneal nerve sensory and motor conduction velocity and ulnar nerve compound motor active potential amplitude were inversely correlated with urinary methylmalonic acid/creatinine. Urinary methylmalonic acid correlates with serum vitamin B12 levels in person with diabetes and is a sensitive marker of early polyneuropathy.
plasma concentration [9]. MMA is biochemically more stable in urine than in serum and has a 40-fold greater concentration in urine [10]. Urinary methylmalonic acid (uMMA) concentration offers a potentially useful functional marker of Vit B12 status. Moreover, the measurement of uMMA would be a less invasive method for the purpose of screening or epidemiologic studies. In addition, uMMA is excreted very efficiently by the kidneys, which concentrates the metabolite in the urine and makes it a sensitive indicator of tissue depletion [10].

Based on the above considerations, we believed that uMMA was an intermediate metabolite during the course of neuropathy, and there was an important relationship between uMMA and the formation of neuropathy. The aim of the present study was to assess uMMA levels in patients presenting with and without diabetic polyneuropathy (DPN) and to determine the role of uMMA in DPN.

2. Subjects, Materials, and Methods

2.1. Subject Selection. The study population consisted of 176 Chinese Han patients (male 97 and female 79) with Type 2 diabetes mellitus aged 38–70 y recruited upon admission to the Second Hospital of Shandong University between June in 2009 and June in 2011 who were eligible for the study.

Exclusion criteria were as follows: history of serious heart and lung disease, diabetic kidney disease or other kidney diseases, pernicious anemia, intestinal surgery, and gastrointestinal disease, excluding antibiotics, colchicine, aminosalicylic acid, H2 receptor antagonists and proton pump inhibitors and other effects of gastrointestinal motility drugs, and the patients with the Vit B12 or methylcobalamin treatment. Long-term vegetarians (more than six months) and those refused concurrent electrophysiological or laboratory testing were excluded too.

According to the level of Vit B12, the patients were divided into 3 groups: group A (Vit B12 < 180ng/L, n = 58), group B (Vit B12 180–400ng/L, n = 68), and group C (Vit B12 > 400ng/L, n = 50).

2.2. Detection of Indicators. The fasting blood samples (22mL/person) via venipuncture into EDTA-coated tubes (5mL) for a full blood were counted to check glycosylated hemoglobin A1c (HbA1c), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), serum creatinine (Scr), Vit B12, folic acid, ferritin, homocysteine (Hcy), hemoglobin (HGB), and mean corpuscular volume (MCV). Holotranscobalamin (holoTC) level was determined by microparticle enzyme immunoassay on AxSYM analyzer (both from Abbott, USA). Fasting morning urine samples were for use. Serum samples were stored at −80°C. Approximately 10mL fasting urine samples were stored at −80°C untreated.

The application of stable isotope dilution method for rapid extraction of the solid phase sample by gas chromatography mass spectrometry was used for the determination of blood methylmalonic acid (bMMA) and uMMA. Urinary MMA was expressed relative to urinary creatinine as the uMMA/creatinine.

Diabetic polyneuropathy: the diagnosis of bilateral limb sensory and motor nerve conduction velocity (SNCV/MNCV) and amplitude was performed, according to standard techniques protocols, by means of Keypoint, Dantec equipment, for all individuals. Tests were carried out in a warm room to minimize the effects of temperature on nerve conduction velocity (CV), and the limbs were warmed throughout with an infrared lamp to maintain a skin temperature over 35°C. Suprathreshold stimulation was used, the frequency was 1Hz (feeling) and 1Hz (movement), respectively, and course was both for 0.2ms. Nerve conduction and electromyographic studies were performed in four limbs, which included 2 nerves of upper limbs and 2 nerves of lower limbs, by means of standard techniques. We measured the amplitude and velocity of motor nerve conduction and sensor nerve conduction in 4 nerves: superficial peroneal, sural, median, and ulnar.

2.3. Statistical Analysis. All experimental data were analysed by SPSS software 16.0 (SPSS, Chicago, IL, USA). Measurement data were presented as mean ± standard deviation (mean ± SD). Single factor and multifactor ANOVA analysis were for the mean difference among the groups. Correlation was analysed using Pearson correlation. The count data were analyzed by χ² test, and logistic regression analysis was used for an independent risk factor of diabetic polyneuropathy. P < 0.05 was considered statistically significant.

3. Results

3.1. Analysis of Clinical Characteristics (See Table 1). Patients in the two groups with normal Vit B12 had decreased serum concentrations of HDL, ferritin, folic acid, holoTC, and HGB and increased uMMA/creatinine and bMMA compared to those lack Vit B12. In addition, DM Type 2 patients with Vit B12 over 400ng/L had significantly increased ferritin, holoTC, and HGB and decreased uMMA/creatinine compared to those with Vit B12 180–400ng/L. There was no significant difference in LDL, MCV, duration, Scr, TG, BMI, and HbAlc among the three groups. Polyneuropathy was present in 24.7% of our diabetic patients using electromyogram.

3.2. Multiple Regression Analysis. Multiple regression analysis revealed that uMMA/creatinine (P = 0.001), bMMA (P = 0.02), diabetes duration (P = 0.045), and holoTC (P = 0.003) were variables that influenced DPN significantly and independently while the serum concentration of Vit B12 did not have an independent significant influence on DPN (Table 2).

3.3. Prevalence of Electrophysiological Markers of Neuropathy Severity according to Urinary Methylmalonic Acid/Creatinine. To value the relationship between uMMA/creatinine and DPN, we separated data according to whether uMMA/creatinine was normal or elevated. It was observed that nerve sensory conduction velocity and nerve amplitude in the group of uMMA/creatinine >3.5 mmol/mol decreased significantly. All individual nerve conduction parameters
Table 1: Comparison of the clinical data among the three groups.

| Parameters                                      | Group A         | Group B         | Group C         |
|------------------------------------------------|-----------------|-----------------|-----------------|
| Age (year)                                      | 58.24 ± 10.53   | 55.81 ± 10.83   | 56.98 ± 10.72   |
| Male/female                                     | 30/28           | 36/32           | 28/22           |
| Duration (year)                                 | 6.28 ± 6.6      | 4.67 ± 5.88     | 4.13 ± 4.77     |
| Vitamin B12 (ng/L)                              | 127.53 ± 60.71  | 303.62 ± 109.98 | 662.86 ± 260.92 |
| BMI (Kg/m²)                                     | 26.06 ± 3.61    | 26.10 ± 3.31    | 25.93 ± 4.09    |
| Hemoglobin A1c (%)                              | 9.12 ± 2.33     | 9.42 ± 2.13     | 8.38 ± 1.97     |
| Triglycerides (mmol/L)                          | 1.79 ± 0.86     | 2.12 ± 1.81     | 1.81 ± 0.88     |
| High-density lipoprotein cholesterol (mmol/L)   | 1.20 ± 0.24     | 1.31 ± 0.28*    | 1.39 ± 0.31*    |
| Low-density lipoprotein cholesterol (mmol/L)    | 2.72 ± 0.80     | 2.84 ± 0.63     | 2.01 ± 1.23     |
| Serum creatinine (umol/L)                       | 60.00 ± 4.32    | 65.89 ± 4.71    | 61.08 ± 4.46    |
| Hemoglobin (g/L)                                | 130.10 ± 18.54  | 136.65 ± 14.58* | 146.71 ± 10.01* |
| Mean corpuscular volume (fl)                    | 85.32 ± 5.60    | 86.66 ± 8.36    | 87.38 ± 9.98    |
| Ferritin (ug/L)                                 | 166.44 ± 92.51  | 225.18 ± 103.06*| 259.33 ± 119.33*|
| Folic acid (ng/L)                               | 6.17 ± 2.06     | 6.50 ± 2.18*    | 6.58 ± 2.32*    |
| Holotranscobalamin (pmol/L)                     | 54.82 ± 30.47   | 70.10 ± 26.00*  | 81.32 ± 32.91ab|
| Urinary methylmalonic acid/creatinine           | 8.04 ± 2.19     | 4.15 ± 1.06*    | 2.75 ± 0.71ab   |
| Blood methylmalonic acid (mmol/L)               | 400.09 ± 80.52  | 370.57 ± 110.9* | 350.72 ± 120.02*|
| Metformin drug usage (%)                        | 80              | 76              | 79              |
| Polynucleopathy (%)                             | 35              | 21              | 18              |

Values are means ± SD. *P < 0.05 compared to group A; †P < 0.05 compared to group B; ‡P < 0.01 compared to group A; §P < 0.01 compared to group B.

Table 2: Logistic analysis of influencing factors of diabetic polyneuropathy.

| Parameters                                      | OR value (95% CI) | P value |
|------------------------------------------------|-------------------|---------|
| Age (year)                                      | 0.73 (0.84–1.08)  | 0.59    |
| Duration (year)                                 | 1.543 (1.302–1.829)| 0.045   |
| Low-density lipoprotein cholesterol (mmol/L)    | 0.76 (0.63–0.89)  | 0.587   |
| High-density lipoprotein cholesterol (mmol/L)   | 1.03 (0.81–1.42)  | 0.407   |
| Triglycerides (mmol/L)                          | 0.27 (0.11–0.36)  | 0.816   |
| Serum creatinine (umol/L)                       | 1.15 (0.79–1.54)  | 0.313   |
| HbA1c (%)                                       | 1.19 (0.85–1.43)  | 0.254   |
| Mean corpuscular volume (fl)                    | 0.18 (0.11–0.25)  | 0.884   |
| Hemoglobin (g/L)                                | 0.99 (0.70–1.27)  | 0.458   |
| Ferritin (ug/L)                                 | 1.08 (0.93–1.21)  | 0.340   |
| Folic acid (ng/L)                               | 0.92 (0.86–0.96)  | 0.532   |
| Urinary methylmalonic acid/creatinine           | 4.07 (3.15–5.46)  | 0.001   |
| Blood methylmalonic acid (pg/mL)                | 2.152 (1.799–2.42)| 0.02    |
| Vitamin B12                                     | 0.88 (0.794–0.997)| 0.547   |
| Holotranscobalamin (pmol/L)                     | 3.89 (2.77–4.56)  | 0.003   |

except median nerve sensory and motor conduction velocity and ulnar nerve motor conduction velocity were statistically significant between the two groups (see Table 3).

3.4. The Correlation Analysis between Urinary Methylmalonic Acid/Creatinine and Electrophysiological Markers of Neuropathy Severity. Univariate analysis was carried out with the uMMA/creatinine as the outcome variable. Some significant correlations were revealed between the uMMA/creatinine and other electrophysiological markers of neuropathy severity (Table 4). Superficial peroneal nerve sensory and conduction velocity ($r = −0.496$, $P = 0.0005$; $r = −0.327$, $P = 0.003$, resp.) and ulnar nerve sensory active nerve potential amplitude ($r = −0.315$, $P = 0.005$) were inversely correlated with the uMMA/creatinine. Sural nerve compound motor active potential amplitude ($r = −0.196$, $P = 0.02$), sural nerve motor conduction velocity ($r = −0.205$, $P = 0.01$), superficial peroneal nerve compound motor active potential.
Table 3: Prevalence of electrophysiological markers of neuropathy severity according to urinary methylmalonic acid/creatinine.

| Electrophysiological markers of neuropathy severity | uMMAr > 3.5 mmol/mol | uMMAr ≤ 3.5 mmol/mol | P    |
|---------------------------------------------------|-----------------------|-----------------------|------|
| Sural nerve SNAP amplitude (μV)                   | 1.43 ± 0.41           | 2.31 ± 1.02           | 0.03 |
| Sural nerve sensory conduction velocity (m/s)     | 45.35 ± 6.11          | 55.98 ± 9.25          | 0.04 |
| Sural nerve CMAP amplitude (μV)                   | 1.12 ± 0.29           | 2.09 ± 0.91           | 0.001|
| Sural nerve motor conduction velocity (m/s)       | 40.06 ± 4.21          | 53.37 ± 7.24          | 0.005|
| Superficial peroneal nerve SNAP amplitude (μV)    | 3.01 ± 1.07           | 5.56 ± 2.73           | 0.005|
| Superficial peroneal nerve sensory conduction velocity (m/s) | 40.11 ± 3.03       | 47.32 ± 5.93          | 0.023|
| Superficial peroneal nerve CMAP amplitude (μV)    | 5.03 ± 2.15           | 6.01 ± 3.39           | 0.012|
| Superficial peroneal nerve motor conduction velocity (m/s) | 44.73 ± 4.91       | 54.12 ± 6.09          | 0.01 |
| Median nerve sensory conduction velocity (m/s)    | 53.77 ± 5.16          | 55.36 ± 5.95          | 0.08 |
| Median nerve SNAP amplitude (μV)                  | 9.25 ± 3.88           | 11.28 ± 5.06          | 0.034|
| Median nerve motor conduction velocity (m/s)      | 52.62 ± 4.41          | 56.15 ± 5.96          | 0.06 |
| Median nerve CMAP amplitude (μV)                  | 7.31 ± 2.08           | 9.06 ± 3.16           | 0.02 |
| Ulnar nerve sensory conduction velocity (m/s)     | 51.07 ± 5.49          | 58.10 ± 6.44          | 0.032|
| Ulnar nerve SNAP amplitude (μV)                   | 6.93 ± 2.01           | 8.36 ± 3.17           | 0.001|
| Ulnar nerve motor conduction velocity (m/s)       | 57.90 ± 6.25          | 61.32 ± 8.04          | 0.07 |
| Ulnar nerve SNAP amplitude (μV)                   | 6.78 ± 1.84           | 8.16 ± 2.48           | 0.022|

Key: SNAP: sensory active nerve potential; CMAP: compound motor active potential; uMMAr: urinary methylmalonic acid/creatinine.

Table 4: The correlation analysis between urinary methylmalonic acid/creatinine and electrophysiological markers of neuropathy severity.

| Electrophysiological markers of neuropathy severity | r          | P     |
|---------------------------------------------------|------------|-------|
| Sural nerve SNAP amplitude (μV)                   | -0.131     | -0.06 |
| Sural nerve sensory conduction velocity (m/s)     | -0.120     | -0.065|
| Sural nerve CMAP amplitude (μV)                   | -0.196     | -0.02 |
| Sural nerve motor conduction velocity (m/s)       | -0.205     | -0.01 |
| Superficial peroneal nerve SNAP amplitude (μV)    | -0.0034    | -0.69 |
| Superficial peroneal nerve sensory conduction velocity (m/s) | -0.496     | -0.0005|
| Superficial peroneal nerve CMAP amplitude (μV)    | -0.197     | -0.015|
| Superficial peroneal nerve motor conduction velocity (m/s) | -0.327     | -0.003|
| Median nerve sensory conduction velocity (m/s)    | -0.115     | -0.07 |
| Median nerve SNAP amplitude (μV)                  | -0.089     | -0.15 |
| Median nerve motor conduction velocity (m/s)      | -0.139     | -0.055|
| Median nerve CMAP amplitude (μV)                  | -0.002     | -0.86 |
| Ulnar nerve sensory conduction velocity (m/s)     | -0.187     | -0.02 |
| Ulnar nerve CMAP amplitude (μV)                   | -0.315     | -0.005|
| Ulnar nerve motor conduction velocity (m/s)       | -0.009     | -0.60 |
| Ulnar nerve SNAP amplitude (μV)                   | -0.125     | -0.065|

SNAP: sensory active nerve potential; CMAP: compound motor active potential.

amplitude ($r = -0.197$, $P = 0.015$), and ulnar nerve sensory conduction velocity ($r = -0.187$, $P = 0.02$) showed modest inverse correlations with uMMA/creatinine.

4. Discussion

Our data showed polyneuropathy was present in 24.7% of our diabetic patients using electromyogram (EMG), which was higher than the previous report [11], maybe because of sample selection or the diagnostic criteria of neuropathy. We demonstrated a significant association between polyneuropathy and duration of diabetes in our patients and no association with age, while, in the Knuiman and Young studies, neuropathy was correlated with age and duration of diabetes [12, 13]. This may reflect the age distribution (all were below 70 years of age in the study).

The bMMA level in the patients with Vit B12 deficiency was significantly higher than in the people with normal Vit B12, while there was no significant difference between the two groups with normal Vit B12, which meant bMMA was not sensitive for early vitamin B12 deficiency. It is not considered the gold standard for the determination of Vit B12 deficiency.
polyneuropathy, according to [23]. The correlation analysis was a manifestation of a more widespread demyelinating amplitude in our patients also raises the possibility that it ulnar nerve. The presence of conduction block and abnormality in the superficial peroneal and sural nerves in [21].

The nerve conduction velocity and amplitude of four limbs decreased obviously as uMMA/creatinine was above normal. There was no significant difference between the decreased conduction velocity of median and ulnar nerves and the increased uMMA/creatinine. The upper limb sensory nerves appeared to be preferably affected by axonal damage as demonstrated by the finding that the sensory active nerve potential amplitude of the median and ulnar nerves was reduced in a remarkably high percentage of study patients, versus the conduction velocity of the two nerves [22]. The abnormality in the superficial peroneal and sural nerves in the lower limb was more severe than in the median and ulnar nerve. The presence of conduction block and abnormal amplitude in our patients also raises the possibility that it was a manifestation of a more widespread demyelinating polyneuropathy, according to [23]. The correlation analysis showed that the nerve conduction block of lower limbs was more serious in the group of the increment of uMMA/creatinine.

Our findings were presented with some limitations. Although we identified patients prospectively, they were not randomly selected from a population with Type 2 diabetes with or without DPN. We underwent EMG for each patient. Being an invasive operation, EMG could not reflect early neuropathy screening, so some early neuropathy patients might be missed. We excluded the patients with Type 1 diabetes because of their expected metformin restriction and the distinct pathophysiological mechanisms, and further study would be conducted in depth.

In conclusion, uMMA and holoTC are significantly associated with cobalamin deficiency and polyneuropathy. The relationships among cobalamin deficiency, decline holoTC, elevated uMMA levels, and the polyneuropathy are controversial, and further work is needed to prove a direct causal relationship and the mechanism, but both cobalamin deficiency and elevation of its serum metabolites are associated with the presence of a sensorimotor peripheral neuropathy [24]. uMMA may exacerbate polyneuropathy as a result of other unknown mechanisms; a clear understanding of its role necessarily awaits further research on the pathogenesis of DPN. Despite these limitations, we believe that uMMA is a potential iatrogenic contributor to the severity of the polyneuropathy in the population described. It can be recommended that uMMA, alone and in combination with holoTC, has better diagnostic efficiency in diagnosing Vit B12 deficiency for the diabetic patients and is expected to become more sensitive predicting and monitoring indicators of diabetic polyneuropathy.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

Funding for this study was provided by the research Grants from the Scientific and Technological Projects of Shandong Province (2009GG20002093), National Natural Science Foundation of China (81070641), and the Scientific and Technological Projects of Shandong Province (2010GSF10231).

References

[1] M. Davies, S. Brophy, R. Williams, and A. Taylor, “The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes,” Diabetes Care, vol. 29, no. 7, pp. 1518–1522, 2006.
[2] S. J. Benbow, M. E. Wallymahmed, and I. A. Macfarlane, “Diabetic peripheral neuropathy and quality of life,” QJM, vol. 91, no. 11, pp. 733–737, 1998.
[3] S. Tesfaye, “Advances in the management of diabetic peripheral neuropathy,” Current Opinion in Supportive and Palliative Care, vol. 3, no. 2, pp. 136–143, 2009.
[4] J. D. England, G. S. Gronseth, G. Franklin et al., “Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation,” Neurology, vol. 72, no. 2, pp. 177–184, 2009.
[5] J. Lindenbaum, D. G. Savage, S. P. Stabler, and R. H. Allen, “Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations,” American Journal of Hematology, vol. 34, no. 2, pp. 99–107, 1990.
[6] D. B. Matchar, D. C. McCrory, D. S. Millington, and J. R. Feussner, “Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency,” American Journal of the Medical Sciences, vol. 308, no. 5, pp. 276–283, 1994.
[7] M. I. Behrens, J. Koh, L. M. T. Canzoniero, S. L. Sensi, C. A. Czernansky, and D. W. Choi, “3-Nitropropionic acid
induces apoptosis in cultured striatal and cortical neurons,” *NeuroReport*, vol. 6, no. 3, pp. 545–548, 1995.

[8] G. D. Zeek, E. Derr-Yellin, and W. J. Nicklas, “Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 275, no. 3, pp. 1124–1130, 1995.

[9] E. V. Cox and A. M. White, “Methylmalonic acid excretion: an index of vitamin-B12 deficiency,” *The Lancet*, vol. 280, no. 7261, pp. 853–856, 1962.

[10] D. B. Matchar, J. R. Feussner, and D. S. Millington, “Isotope-dilution assay for urinary methylmalonic acid in the diagnosis of vitamin B12 deficiency. A prospective clinical evaluation,” *Annals of Internal Medicine*, vol. 106, no. 5, pp. 707–710, 1987.

[11] B. Lu, J. Hu, J. Wen et al., “Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-Diabetes- ShangHai Diabetic neuropathy epidemiology and molecular genetics study (SH-DREAMS),” *PloS One*, vol. 8, no. 4, Article ID e61053, 2013.

[12] M. W. Knuiman, T. A. Welborn, and V. J. McCann, “Prevalence of diabetic complications in relation to risk factors,” *Diabetes*, vol. 35, no. 12, pp. 1332–1339, 1986.

[13] M. J. Young, A. J. M. Boulton, A. F. Macleod, D. R. R. Williams, and P. H. Sonksen, “A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population,” *Diabetologia*, vol. 36, no. 2, pp. 150–154, 1993.

[14] R. Clarke, H. Refsum, J. Birks et al., “Screening for vitamin B-12 and folate deficiency in older persons,” *American Journal of Clinical Nutrition*, vol. 77, no. 5, pp. 1241–1247, 2003.

[15] A. L. Bjørke Monsen and P. M. Ueland, “Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence,” *American Journal of Clinical Nutrition*, vol. 78, no. 1, pp. 7–21, 2003.

[16] A. Lindgren, A. Kilander, E. Bagge, and E. Nexo, “Holotranscobalamin—a sensitive marker of cobalamin malabsorption,” *European Journal of Clinical Investigation*, vol. 29, no. 4, pp. 321–329, 1999.

[17] E. Nexo and E. Hoffmann-Lücke, “Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility,” *American Journal of Clinical Nutrition*, vol. 94, no. 1, pp. 359S–365S, 2011.

[18] J. E. Flatley, C. M. Garner, M. Al-Turki et al., “Determinants of urinary methylmalonic acid concentration in an elderly population in the United Kingdom,” *American Journal of Clinical Nutrition*, vol. 95, no. 3, pp. 686–693, 2012.

[19] E. J. Norman, “Urinary methylmalonic acid test may have greater value than the total homocysteine assay for screening elderly individuals for cobalamin deficiency,” *Clinical Chemistry*, vol. 50, no. 8, pp. 1482–1483, 2004.

[20] E. Rota, R. Quadri, E. Fanti et al., “Electrophysiological findings of peripheral neuropathy in newly diagnosed type II diabetes mellitus,” *Journal of the Peripheral Nervous System*, vol. 10, no. 4, pp. 348–353, 2005.

[21] J. A. Acosta, S. N. Hoffman, E. M. Raynor, R. A. Nardin, and S. B. Rutkove, “Ulnar neuropathy in the forearm: a possible complication of diabetes mellitus,” *Muscle and Nerve*, vol. 28, no. 1, pp. 40–45, 2003.

[22] B. Lu, J. Hu, J. Wen et al., “Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-Diabetes- ShangHai Diabetic neuropathy epidemiology and molecular genetics study (SH-DREAMS),” *PloS One*, vol. 8, no. 4, Article ID e61053, 2013.

[23] M. W. Knuiman, T. A. Welborn, and V. J. McCann, “Prevalence of diabetic complications in relation to risk factors,” *Diabetes*, vol. 35, no. 12, pp. 1332–1339, 1986.